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Abstract:
Efficacy of ceftaroline fosamil, the prodrug of the active metabolite 
ceftaroline, was demonstrated in a phase 3 study of hospitalized Asian 
patients with Pneumonia Outcomes Research Team (PORT) risk class III-
IV community-acquired pneumonia (CAP) (NCT01371838). The 
objectives of the current analysis were to expand an existing ceftaroline 
and ceftaroline fosamil population pharmacokinetic (PK) model with data 
from this phase 3 study and a phase 1 study (NCT01458743) assessing 
ceftaroline PK in Chinese healthy volunteers, and to evaluate probability 
of PK/pharmacodynamic (PK/PD) target attainment (PTA) in Asian 
patients with CAP treated with ceftaroline fosamil. Ceftaroline plasma 
concentration–time courses were simulated for 5000 Asian patients with 
CAP for different renal function subgroups using the final model. PTAs 
were calculated for Streptococcus pneumoniae, Staphylococcus aureus 
and non-extended-spectrum β-lactamase-producing Enterobacteriaceae. 
PTAs were also evaluated at ceftaroline MIC90 values of isolates collected 
from Asia-Pacific surveillance studies (2012–2014), and at EUCAST and 
FDA/CLSI ceftaroline susceptibility breakpoints. The final model 
reasonably described the ceftaroline PK. Race was found not to be a 
significant covariate impacting ceftaroline PK, suggesting similar 
ceftaroline PK in Asian and Western populations when corrected for body 
weight. High PTAs (90–100%) were predicted for Asian patients with CAP 
treated with ceftaroline fosamil, covering MIC90 values of target CAP 
pathogens from the region. Similarly, >90% PTAs were predicted at 
EUCAST and FDA/CLSI clinical breakpoints for these pathogens. These 
results support use of the ceftaroline fosamil dosing regimens approved 
in Europe and the United States in Asian patients with PORT III-IV CAP.
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Abstract
Efficacy of ceftaroline fosamil, the prodrug of the active metabolite ceftaroline, was 
demonstrated in a phase 3 study of hospitalized Asian patients with Pneumonia 
Outcomes Research Team (PORT) risk class III-IV community-acquired pneumonia 
(CAP) (NCT01371838). The objectives of the current analysis were to expand an 
existing ceftaroline and ceftaroline fosamil population pharmacokinetic (PK) model 
with data from this phase 3 study and a phase 1 study (NCT01458743) assessing 
ceftaroline PK in Chinese healthy volunteers, and to evaluate probability of 
PK/pharmacodynamic (PK/PD) target attainment (PTA) in Asian patients with CAP 
treated with ceftaroline fosamil. Ceftaroline plasma concentration-time courses were 
simulated for 5000 Asian patients with CAP for different renal function subgroups 
using the final model. PTAs were calculated for Streptococcus pneumoniae, 
Staphylococcus aureus and non–extended-spectrum β-lactamase-producing 
Enterobacteriaceae. PTAs were also evaluat d at ceftaroline MIC90 values of 
isolates collected from Asia-Pacific surveillance studies (2012-2014), and at 
EUCAST and FDA/CLSI ceftaroline susceptibility breakpoints. The final model 
reasonably described the ceftaroline PK. Race was found not to be a significant 
covariate impacting ceftaroline PK, suggesting similar ceftaroline PK in Asian and 
Western populations when corrected for body weight. High PTAs (90-100%) were 
predicted for Asian patients with CAP treated with ceftaroline fosamil, covering MIC90 
values of target CAP pathogens from the region. Similarly, >90% PTAs were 
predicted at EUCAST and FDA/CLSI clinical breakpoints for these pathogens. These 
results support use of the ceftaroline fosamil dosing regimens approved in Europe 
and the United States in Asian patients with PORT III-IV CAP.
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Introduction
Community-acquired pneumonia (CAP) causes significant morbidity and mortality 
worldwide and is associated with a substantial clinical and economic burden in the 
Asia-Pacific region.1 Ceftaroline, the active metabolite of the prodrug ceftaroline 
fosamil, is a cephalosporin with in vitro activity against many of the major bacterial 
pathogens causing CAP, including the Gram-positive cocci such as Streptococcus 
pneumoniae and Staphylococcus aureus, and non–extended-spectrum β-lactamase 
(ESBL) producing Gram-negative bacteria such as Haemophilus influenzae, 
Escherichia coli, and Klebsiella pneumoniae.
The efficacy and safety of ceftaroline fosamil for the treatment of CAP has been 
assessed in 3 phase 3 studies. The FOCUS 1 and 2 studies (NCT00621504 and 
NCT0050910) included predominantly European and North American patients and 
demonstrated the noninferiority of ceftaroline fosamil 600 mg every 12 hours (q12h) 
versus ceftriaxone 1 g every 24 hours (q24h) in patients hospitalized with 
Pneumonia Outcomes Research Team (PORT) risk class III or IV CAP.2,3 
Subsequently, a phase 3 study (NCT01371838) in Asian patients hospitalized with 
PORT III-IV CAP demonstrated the superiority of ceftaroline fosamil 600 mg q12h 
versus ceftriaxone 2 g q24h.4 A meta-analysis of these 3 studies demonstrated there 
was no evidence of heterogeneity between the studies, with clinical cure rates in 
each trial consistently favoring ceftaroline fosamil versus ceftriaxone.5 Ceftaroline 
fosamil 600 mg q12h as a 1-hour IV infusion is approved in Europe for the treatment 
of adult and adolescent patients with CAP or complicated skin and soft tissue 
infections (cSSTI), and is also approved for similar indications in the United States 
and multiple other countries. Due to the predominantly renal excretion of ceftaroline, 
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dosage adjustments are required for patients with creatinine clearance (CrCL) ≤50 
mL/min.6
The pharmacokinetic (PK) profile of ceftaroline has been well-characterized in 
several phase 1 studies.6 Following intravenous (IV) administration, the prodrug 
ceftaroline fosamil is rapidly converted into the active metabolite ceftaroline by 
plasma phosphatases.6 Concentrations of the prodrug are measurable in plasma 
primarily during IV infusion and are typically not quantifiable beyond one hour 
following the end of IV infusion.6,7 After conversion to ceftaroline, a small fraction is 
converted into an inactive metabolite, ceftaroline-M-1.6 The primary route of 
elimination for ceftaroline fosamil and its metabolites is by renal clearance; between 
40-70% of the ceftaroline fosamil dose is excreted in the urine as ceftaroline.6 
Ceftaroline exposures increase in a dose-proportional manner within the single dose 
range of 50 to 1000 mg and the mean terminal elimination half-life of ceftaroline in 
healthy adults is approximately 2.5 hours.6 No clinical studies have assessed drug-
drug interactions for ceftaroline fosamil, however as ceftaroline is not a substrate, 
inhibitor or inducer of major hepatic CYP450 enzymes in vitro, the overall drug-drug 
interaction potential is considered low.6 
PK modelling and simulation play an important role in guiding the selection and 
validation of antibiotic dosage regimens.8,9 PK data obtained for the antibiotic in the 
patient population of interest are used to develop population PK models which 
describe the concentration–time course of the antibiotic and characterize the effect 
of subject characteristics (covariates) on the PK parameters, while also accounting 
for random variability in concentrations within the patient population.8,9 Using model 
parameters including variability, antibiotic concentration-time courses are simulated 
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for a large patient populations receiving the intended dosage regimen (Monte Carlo 
simulations). These simulations can be used to determine the proportion of patients 
that achieve a pre-specified PK/PD target associated with antibiotic efficacy (typically 
derived from preclinical studies) and thus the probability of target attainment (PTA). 
The PTA values achieved across the antibiotic minimum inhibitory concentration 
(MIC) distributions of target pathogens can be used to inform dosing decisions.
A population PK model for ceftaroline and ceftaroline fosamil was initially developed 
based on adult PK data from healthy volunteers and phase 2 and 3 studies in 
patients with cSSTI10 and subsequently updated to include data for patients with 
CAP from the FOCUS studies (unpublished data); a separate population PK model 
was also subsequently developed which included data from clinical trials in pediatric 
patients.11 The clinical studies on which the original model was based primarily 
enrolled patients from Western countries. Two trials of ceftaroline fosamil have now 
been completed in Asian patients: the phase 3 Asia CAP study, and a phase 1 study 
in Chinese healthy volunteers (NCT01458743), which found broadly similar 
ceftaroline PK in healthy Chinese and Western subjects receiving equivalent twice- 
and three-times daily dosage regimens.12 The objectives of the current analysis were 
to extend the previous ceftaroline and ceftaroline fosamil population PK model with 
PK data from these Asian studies, and to use the updated model to evaluate the 
PTA against key CAP pathogens in simulated Asian patients with CAP treated with 
ceftaroline fosamil.
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Methods
Model Dataset
All studies included in the population PK model were performed in accordance with 
ethical principles that have their origin in the Declaration of Helsinki and that were 
consistent with the International Conference on Harmonization. The clinical study 
protocols, informed consent form(s), and all other appropriate study-related 
documents were reviewed and approved by local independent ethics committees / 
institutional review boards. A summary of all the studies included in this analysis is 
presented in Supplementary Table 1. 
A previously developed population PK model for ceftaroline and ceftaroline fosamil 
was used as the starting point to develop the model for this analysis. The dataset for 
the original model comprised patient PK data from 16 clinical studies of ceftaroline 
fosamil (11 phase 1, 1 phase 2, and 4 phase 3) that included healthy volunteers and 
patients with CAP or cSSTI (Supplementary Table 1).2,3,6,13-19 Ceftaroline fosamil was 
given as an IV infusion in these studies, except for one study where ceftaroline 
fosamil was intramuscularly administered. These studies were termed the Western 
dataset, although a small proportion of Asian patients were also included. 
To develop the final model, the Western dataset was pooled with data from the 
phase 3 Asia CAP study4 and the phase 1 study in Chinese healthy volunteers.12 
The Asia CAP study included 771 Asian patients with PORT III-IV CAP from study 
centers in China, India, South Korea, Taiwan, and Vietnam who were randomized 
1:1 to receive either ceftaroline fosamil 600 mg q12h (adjusted to 400 mg q12h in 
patients with moderate renal impairment [CrCL >30-50 mL/min]) or ceftriaxone 2 g 
q24h. Data for PK analysis were obtained from sparse plasma sampling (maximum 
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of 4 samples per patient) in 86 Asian patients with CAP treated with ceftaroline 
fosamil in this study. Blood samples for PK analysis were obtained at the following 
times on day 3: within 15 minutes prior to the start of infusion 1, within 5 minutes 
following the end of infusion 2, between 1 and 3 hours after the end of infusion 2, 
and between 4 and 8 hours after the end of infusion 2. In total, there were 333 
observed ceftaroline concentrations from these 86 patients. The phase 1 study 
included 26 Chinese subjects from a single study center in Beijing who received 
either a single 1-hour infusion of 600 mg ceftaroline fosamil on day 1 and day 8, and 
1-hour infusions of ceftaroline fosamil 600 mg q12h on days 3 to 7 or a 2-hour 
infusion of 600 mg ceftaroline fosamil on day 1 and day 8, and 2-hour infusions of 
ceftaroline fosamil 600 mg every 8 hours (q8h) on days 2 to 7. PK data were 
obtained from intensive plasma concentration sampling throughout the study in all 26 
subjects. Blood samples for PK analysis were obtained on days 1 and 8 at predose 
and at predefined intervals up to 48 hours after the start of infusion. A total of 740 
observed ceftaroline concentrations were obtained from all 26 subjects. 
Bioanalytical methods
Validated liquid chromatography coupled with tandem mass spectrometry (LC-
MS/MS) methods were used to measure plasma concentrations of ceftaroline and 
ceftaroline fosamil in each study, apart from one study in which a validated high 
pressure liquid chromatography method with ultraviolet detection method was used 
(see Supplementary material for further details).10 Lower limit of quantification 
(LLOQ) values for each study are summarized in Supplementary Table 1.  
Ceftaroline and ceftaroline fosamil concentrations reported as missing or below the 
LLOQ were expressed as missing for subjects/patients with dense PK sampling. 
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Model Development
The population PK model for ceftaroline and ceftaroline fosamil in the current 
analysis was developed using NONMEM™ version 7.2.0 and the stepwise covariate 
model building procedure in Perl-speaks-NONMEM. Estimation of population PK 
parameters was performed using the first-order conditional estimation method with 
interaction (FOCE-I). 
The previous population PK model of ceftaroline and ceftaroline fosamil based on 
the Western dataset was described by a two-compartment disposition model for 
ceftaroline fosamil with an absorption compartment for intra-muscular dose 
administration and a two-compartment disposition model for ceftaroline assuming a 
complete conversion of ceftaroline fosamil to ceftaroline. Age, end-stage renal 
disease (ESRD) in nondialysis subjects, participant status (ie, with infection or 
healthy volunteers), and body surface area-normalized creatinine clearance (NCrCL; 
calculated using the Cockcroft-Gault method) were identified as significant 
covariates impacting the clearance (CL) of ceftaroline, and patients versus healthy 
volunteers was identified as a significant covariate impacting the central volume of 
distribution (Vc) of ceftaroline.
The previous model was adapted by fixing the ceftaroline fosamil PK parameters and 
excluding the ceftaroline fosamil concentrations to ensure numerical stability of the 
modeling computation, and by incorporating standard allometric models of body 
weight on CL and Vc parameters of ceftaroline fosamil and ceftaroline. The adapted 
model was used to re-evaluate the significance of the previously identified significant 
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covariates using the pooled Western and Asian dataset by a stepwise backward 
elimination procedure. 
To develop the final model, the effect of the race covariate (ethnicity defined by 
Caucasian, Black, Asian, and Other) on ceftaroline CL and Vc was evaluated using a 
forward selection and a backward elimination procedure for the pooled dataset (P 
value set to .001 for both the forward and backward selection). Conditional weighted 
residuals (CWRES; calculated as the FOCE approximated difference between an 
individual’s data and the model prediction of that data divided by the root of the 
covariance of the data given the model)20 with values >4 were removed in an 
iterative procedure to avoid undue influence of outlier values in the model.
Model Evaluation
Standard goodness of fit model diagnostic plots and the OFV provided by NONMEM 
were used during model development to evaluate the fit of the models to the data. 
The following model diagnostic plots were used: observed ceftaroline concentrations 
versus individual predictions (IPRED) or population predictions (PRED), individual 
weighted residual (IWRES) versus IPRED, and CWRES versus PRED. In addition, 
prediction-corrected visual predictive checks (pcVPC) with 95% confidence intervals 
were used to evaluate the predictive performance of the models. As the study design 
and covariates included in the model differed widely among studies and study arms, 
pcVPC was used instead of the traditional VPC approach.21 In pcVPC, the observed 
and the simulated dependent variables are normalized based on the typical 
population prediction, which facilitates the evaluation of models based on data with a 
wide range in the dependent variables. For the pcVPCs, 1000 datasets were 
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simulated using the doses and covariate data from the subjects that were used in the 
analysis dataset with the same study design. The observed and simulated ceftaroline 
concentration versus time profiles were compared graphically.
In this analysis, the ceftaroline fosamil PK parameters were fixed and the ceftaroline 
fosamil observations were therefore excluded in the development of the final model. 
The ability of the final model to predict the ceftaroline observations when the 
ceftaroline fosamil observations were excluded was evaluated by reintroducing the 
ceftaroline fosamil concentrations into the final model and performing similar model 
diagnostic plots and pcVPC plots to those described above.
Exposure Indices
Individual empirical Bayes estimates of PK parameters were used to predict 
individual ceftaroline exposure indices for area under the concentration-time curve at 
steady-state (AUCss) and maximum concentration at steady state (Cmax,ss) and to 
derive an individual secondary ceftaroline parameter (terminal half-life of ceftaroline 
[T1/2]). Exposure indices were calculated for 4 groups of Asian subjects at steady-
state according to the ceftaroline fosamil dosage regimens administered in the phase 
1 study in Chinese healthy volunteers and the phase 3 Asia CAP study: phase 1 
subjects receiving 600 mg q12h 1-hour infusions, phase 1 subjects receiving 600 mg 
q8h 2-hour infusions, phase 3 patients receiving 600 mg q12h 1-hour infusions, and 
phase 3 patients receiving 400 mg q12h 1-hour infusions.
Monte Carlo Simulations
Monte Carlo simulation generates a set of PK parameter values for each simulated 
patient by random sampling within the predefined PK parameter distribution from the 
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population PK model.8 Ceftaroline concentration-time courses were simulated in 
5000 Asian patients with CAP using the final population PK model. Individual patient 
PK parameters were simulated from the population model mean PK parameters, 
associated individual covariates from the covariate distribution, and inter-subject 
variability from the final model. To simulate individual patient covariates, random 
samples of age, body weight, body surface area (BSA), and CrCL were drawn from 
the multivariate normal distribution of these covariates at baseline in the 771 Asian 
patients from the Asia CAP study. The NCrCL was calculated as CrCL*1.73/BSA. In 
addition, 5000 covariate datasets were constructed for each of 3 subgroups based 
on subjects’ renal function: normal (CrCL >80 mL/min), mild impairment (CrCL >50-
80 mL/min), or moderate impairment (CrCL >30-50 mL/min).
PK/PD Targets 
In similarity to other β-lactam antibiotics, the PK/PD index associated with in vitro 
and in vivo efficacy for ceftaroline is the percentage of time during the dosing interval 
that free drug plasma concentrations exceed the minimum inhibitory concentration of 
the bacteria (%fT>MIC).22,23 PK/PD targets are the PK/PD index values for which the 
desired level of antibiotic efficacy is achieved (e.g. stasis, 1-log10 reduction or 2-log10 
reduction in bacterial density of the infecting pathogen). Ceftaroline PK/PD targets 
for S. pneumoniae and Enterobacteriaceae were derived from a neutropenic murine 
thigh and lung infection model.23 Median (range) %fT>MIC targets for S. 
pneumoniae were 35% (29-52%) for stasis, 44% (33-59%) for 1-log10 reduction, and 
51% (36-64%) for 2-log10 reduction; for Enterobacteriaceae, median (range) 
%fT>MIC targets were 48.5% for stasis and 73% (39-89%) for 1-log10 reduction.23 
PK/PD targets for S. aureus were derived from 3 preclinical studies23-25 and the 
mean %fT>MIC targets from these studies were used in this analysis: 27% for stasis, 
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31% for 1-log10 reduction, and 35% for 2-log10 reduction.26 For non–species-specific 
PK/PD targets, targets of 20-80% fT>MIC with 10% increments were used.
The simulated steady-state ceftaroline plasma concentration-time courses were used 
to obtain the %fT>MIC for each patient during the dosing interval. A free fraction of 
80% was applied for the ceftaroline plasma concentrations used for %fT>MIC 
calculations. 
PTA Simulations
PTAs were calculated as the percentage of 5000 simulated patients in each renal 
function subgroup at steady state who met the species-specific or non–species-
specific PK/PD targets described above for a range of MICs following administration 
of the approved ceftaroline fosamil dosing regimens for each subgroup: 600 mg as a 
1-hour IV infusion q12h for subjects with normal renal function or mild renal 
impairment, and 400 mg as a 1-hour IV infusion q12h for subjects with moderate 
renal impairment. 
Achievement of >90% PTA was used to evaluate the appropriateness of the 
ceftaroline fosamil dosage regimen at a given MIC value. PTAs were calculated for 
MIC values of 0.125, 0.5, 1, 2, 4, and 8 mg/L. The PTAs at the highest ceftaroline 
MIC values of isolates collected from the Asia CAP study4 and the MIC90 values (MIC 
required to inhibit 90% of isolates) of clinical isolates obtained from recent Asia-
Pacific antibiotic susceptibility surveillance studies were determined. MIC90 values 
were recorded for clinical isolates of S. pneumoniae (penicillin-susceptible, penicillin-
intermediate, and penicillin-resistant), S. aureus (methicillin-sensitive and methicillin-
resistant; MSSA and MRSA), E. coli and K. pneumoniae collected in the Asia-Pacific 
region during 2012, 2013, and 2014 as part of the AWARE ceftaroline surveillance 
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program.27,28 In the 2013 and 2014 surveillance studies, a ceftazidime or aztreonam 
MIC of >1 mg/L was used as a phenotypic marker to define ESBL-positive 
Enterobacteriaceae isolates.29 The PTA by MIC curves for each PK/PD target and 
ceftaroline MIC frequency distributions from the 2014 Asia-Pacific surveillance study 
were co-plotted for visual examination of appropriate PTA coverage for S. 
pneumoniae (penicillin-susceptible, penicillin-intermediate, and penicillin-resistant). 
The PTA was also calculated at the ceftaroline EUCAST and FDA/CLSI clinical 
susceptibility MIC breakpoints established for the q12h dosage regimens against 
S. pneumoniae, S. aureus, Enterobacteriaceae, H. influenzae and the EUCAST 
non–species-specific breakpoint (summarized in Table 5).
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Results
Final Population PK Model
Baseline covariates included in the Western, Asian, and pooled Western and Asian 
analysis datasets for the final model are summarized in Supplementary Table 2. The 
pooled Western and Asian dataset for the final model comprised 533 subjects 
(348 male,185 female) with a median age of 47 years (range 12-93 years) and a 
median body weight of 72 kg (range 40-134 kg). Of these, 221 (41%) were healthy 
volunteers and 312 (59%) were patients with cSSTI or CAP; overall 123 (23%) 
subjects were of Asian ethnicity. In total, 320 (60%) subjects in the pooled Western 
and Asian dataset had normal renal function, 146 (27%) had mild renal impairment, 
52 (10%) had moderate renal impairment, 9 (2%) had severe renal impairment, and 
6 (1%) had ESRD or were on dialysis.
Based on the original Western dataset model, ceftaroline and ceftaroline fosamil 
concentration-time courses were both modeled as 2-compartment disposition PK 
models in the final model, with an assumption of 100% conversion of ceftaroline 
fosamil into ceftaroline and a first-order absorption of ceftaroline fosamil after intra-
muscular administration of ceftaroline fosamil. With the impact of body weight on 
ceftaroline fosamil and ceftaroline CL and Vc fixed to an allometric model, all the 
previously identified significant covariates (age, NCrCL, ESRD in nondialysis 
patients and patients versus healthy volunteers) were still statistically significant (P < 
.001), with the adapted model for the pooled dataset including the Western dataset, 
as well as data from the 2 new Asian studies. Race, including Asian ethnicity as a 
subgroup, was not a significant covariate impacting the CL and Vc of ceftaroline. 
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The final model described the observed ceftaroline concentrations well for all 
subjects in the pooled Western and Asian dataset, as shown by the typical 
goodness-of-fit diagnostic plots (Figure 1), and the pcVPC plots using the final model 
for all subjects (Figure 2) and for patients from the Asia CAP study (Figure S1). 
Thus, the final model was considered appropriate for calculating the PTA in Asian 
patients with CAP. In this analysis, population PK parameters for ceftaroline fosamil 
were fixed and ceftaroline fosamil concentrations were excluded in the development 
of the final model for ceftaroline. However, in a sensitivity analysis where ceftaroline 
fosamil concentrations were re-introduced into the final model, goodness-of-fit plots 
(Figure S2) and the pcVPC plot for ceftaroline (Figure S3) showed that the final 
model still provided a reasonable description of ceftaroline observations. This 
indicated that fixing the PK parameters for ceftaroline fosamil and excluding 
ceftaroline fosamil observations had little impact on the goodness-of-fit to the 
ceftaroline concentrations, and that the final ceftaroline model was therefore suitable 
for the subsequent PTA simulations. Parameter estimates (fixed) for ceftaroline and 
ceftaroline fosamil in the final model are summarized in Table 1. Individual predicted 
exposure indices (AUCss and Cmax,ss) and T1/2 by ceftaroline fosamil dosage regimen 
received in the phase 3 Asia CAP study and the phase 1 study in Chinese healthy 
volunteers are presented in Table 2.
PTA in Asian CAP Patient Population With Normal Renal Function
Streptococcus pneumoniae
PTAs for stasis (35% fT>MIC), 1-log10 kill (44% fT>MIC), and 2-log10 kill (51% 
fT>MIC) for S. pneumoniae were >97% for all PK/PD targets at ceftaroline MICs of 1 
mg/L or lower (Table 3) for patients with normal renal function (CrCL >80 mL/min) 
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receiving the ceftaroline fosamil 600 mg q12h dosing regimen. Ceftaroline MIC90s 
against S. pneumoniae isolates collected from 2012, 2013, and 2014 Asia-Pacific 
surveillance studies ranged from 0.06 to 0.5 mg/L (2012), 0.12 to 0.5 mg/L (2013), 
and 0.12 to 1 mg/L (2014) for penicillin-susceptible (PSSP), penicillin-intermediate 
(PISP), and penicillin-resistant (PRSP) strains (Table 4). For all PK/PD targets, 
>97% PTAs were achieved for these MIC90 values (Table 4). A representative PTA 
by MIC plot for S. pneumoniae overlaid with the ceftaroline MIC distribution for S. 
pneumoniae isolates from the Asia-Pacific region obtained during the 2014 
surveillance program is shown in Figure 3. This shows high PTA coverage for 
ceftaroline across the range of MIC values for real-life clinical isolates. Moreover, the 
highest ceftaroline MIC observed for S. pneumoniae isolates in the Asia CAP study 
was 0.25 mg/L.4 This is within the range of MIC90 values observed in the Asia-Pacific 
surveillance studies in 2012-2014 (Table 4), indicating >97% PTAs can be achieved 
for all the PK/PD targets in Asian patients with CAP caused by S. pneumoniae. 
Across all targets, estimated PTAs for S. pneumoniae were ≥99.9% at the EUCAST 
and FDA/CLSI clinical susceptibility breakpoints (≤0.25 and ≤0.5 mg/L, respectively; 
Table 5).
Staphylococcus aureus
PTAs were greater than 98% for all S. aureus PK/PD targets (27% fT>MIC, 31% 
fT>MIC, and 35% fT>MIC for stasis, 1-log10 kill, and 2-log10 kill, respectively) at 
ceftaroline MICs of 2 mg/L or lower for patients receiving ceftaroline fosamil 600 mg 
q12h (Table 3). This was in close agreement with the ceftaroline MIC90 against 
S. aureus strains (MSSA plus MRSA) isolated in the Asia-Pacific region in the 
surveillance studies from 2012-2014 (Table 4). PTA of >98% was achieved for all 
PK/PD targets at this MIC90 value (Table 3). The maximum ceftaroline MIC against 
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S. aureus isolated from patients in the Asia CAP study was 0.5 mg/L,4 at which 
100% PTA was achieved for all PK/PD targets (Table 3). Estimated PTAs for S. 
aureus at the EUCAST and FDA/CLSI ceftaroline susceptibility breakpoint (≤1 mg/L) 
were 100% for all PK/PD targets (Table 5).
Enterobacteriaceae
PTAs for stasis (48.5% fT>MIC) and 1-log10 kill (73% fT>MIC) by MIC for 
Enterobacteriaceae for patients receiving ceftaroline fosamil 600 mg q12h are shown 
in Table 3, with a PTA of >90% for all MICs up to 0.5 mg/L estimated for a 1-log10 kill 
PK/PD target. In the 2013 and 2014 surveillance studies, ceftaroline MIC90 values 
≤0.5 mg/L against ESBL-negative E. coli and K. pneumoniae were observed; >90% 
PTAs are predicted for the stasis and 1-log10 kill PK/PD targets for these MIC90 
values (Tables 3 and 4). The maximum ceftaroline MIC observed for ESBL-negative 
Enterobacteriaceae in the Asia CAP study4 was 0.5 mg/L. Similar to S. pneumoniae 
and S. aureus, estimated PTAs for ESBL-negative Enterobacteriaceae were all 
>90% at the EUCAST and FDA/CLSI clinical susceptibility breakpoint (≤0.5 mg/L, 
Table 5).
Non–Species-Specific PK/PD Targets
PTA analyses were also conducted for non–species-specific PK/PD targets ranging 
from 20% fT>MIC to 80% fT>MIC for patients receiving the 600 mg q12h dosing 
regimen (Table 6). For lower ceftaroline MIC values (0.125 mg/L and 0.25 mg/L), 
>95% PTAs were predicted for a PK/PD target as high as 80% fT>MIC 
(Supplementary Table 3). For moderate MIC values (1 mg/L and 2 mg/L), >90% 
PTAs were predicted for a PK/PD target of 40% fT>MIC (Table 6). PTAs <7% were 
predicted for ceftaroline at MICs of >2 mg/L and PK/PD targets ≥50% fT>MIC (Table 
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6). Greater than 90% PTA was predicted at the EUCAST non–species-specific 
PK/PD breakpoint of ≤0.5 mg/L with a non–species-specific PK/PD target of ≥70% 
fT>MIC (Table 5). Non–species-specific PK/PD targets were also used to interpret H. 
influenzae susceptibility MIC breakpoints; for the EUCAST breakpoint (MIC ≤0.03 
mg/L) 100% PTAs were predicted at anon–species-specific PK/PD target of 100% 
fT>MIC and for the FDA/CLSI breakpoint (MIC ≤0.5 mg/L) >90% PTA was predicted 
for a non–species-specific target of ≥70% fT>MIC.
PTA in Asian CAP Patient Population With Mild or Moderate Renal Impairment
Similar PTA analyses to those conducted for patients with normal renal function 
receiving ceftaroline fosamil 600 mg q12h were carried out for Asian CAP patients 
with mild renal impairment (CrCL >50-80 mL/min) receiving ceftaroline fosamil 600 
mg q12h and patients with moderate renal impairment (CrCL >30-50 mL/min) 
receiving ceftaroline fosamil 400 mg q12h. In patients with mild or moderate renal 
impairment, the predicted PTAs were similar or slightly higher than those for patients 
with normal renal function (Supplementary Table 4 compared with Table 3, and 
Supplementary Table 5 compared with Table 3).
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Discussion
The phase 3 Asia CAP study demonstrated the superiority of ceftaroline fosamil 
600 mg q12h over ceftriaxone 2 g q24h in Asian patients with PORT III-IV CAP.4 
These data along with data from a phase 1 study in Chinese healthy volunteers12 
were used to update an existing population PK model for ceftaroline and ceftaroline 
fosamil to characterize their population PK and evaluate PTA in a representative 
Asian patient population with CAP treated with ceftaroline fosamil. Compared with an 
earlier ceftaroline and ceftaroline fosamil population PK model that was primarily 
based on Western healthy volunteers and cSSTI patients,10 the model used in this 
analysis included additional data from Phase III patients with CAP and substantially 
more data from Asian subjects treated with ceftaroline fosamil.
The final model described the observed ceftaroline concentrations well for all 
Western and Asian subjects in the dataset. Importantly, race, as defined by ethnicity, 
was not a statistically significant covariate impacting ceftaroline CL or Vc in the final 
model. This finding suggests that the PK characteristics of ceftaroline are similar in 
the Asian and Western populations, when corrected for body weight. Individual 
predicted ceftaroline exposures for Asian subjects derived from the final model were 
similar to those reported for noncompartmental analyses in both Chinese and 
Western subjects.12 Similar ceftaroline exposures are therefore expected in Asian 
and Western subjects with the same body weight receiving the same ceftaroline 
fosamil dosage regimen. This is in agreement with the classification of ceftaroline 
fosamil as a drug (similar to other cephalosporins) that is not sensitive to ethnicity 
according to ICH E5,30 and the finding of the study in healthy volunteers that the PK 
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profiles of ceftaroline and ceftaroline fosamil were similar in Chinese and Western 
subjects.12
PTA simulations were conducted using the covariate distributions from all patients in 
the Asia CAP study to confirm that current ceftaroline fosamil dosing regimens 
provide adequate PTA in an Asian patient population with CAP. High PTAs across all 
PK/PD targets were predicted for Asian patients with CAP treated with ceftaroline 
fosamil; PTAs for ceftaroline ranged from 90-100% for S. pneumoniae, S. aureus, 
and ESBL-negative E. coli or K. pneumoniae isolates, typically covering ceftaroline 
MIC90 values observed in Asia-Pacific surveillance studies between 2012-2014 for 
S. pneumoniae (0.06 to 1 mg/L for PSSP, PISP, and PRSP) and S. aureus (2 mg/L) 
and between 2013-2014 for ESBL-negative E. coli and K. pneumoniae (≤0.5 mg/L). 
Greater than 90% PTAs were also achieved at the EUCAST and FDA/CLSI 
susceptibility breakpoints for S. pneumoniae (≤0.25 and ≤0.5 mg/L), S. aureus (≤1 
mg/L), and Enterobacteriaceae (≤0.5 mg/L). Similarly, >90% PTA was also reached 
at the EUCAST non–species-specific PK/PD breakpoint of ≤0.5 mg/L and for H. 
influenzae EUCAST and FDA/CLSI susceptibility breakpoints (≤0.03 and ≤0.5 mg/L), 
with a PK/PD target of at least 70% fT>MIC. This has clinical implications for dosing 
as the analysis confirmed that the ceftaroline fosamil dosing regimens recommended 
for patients with normal renal function and those with mild renal impairment (600 mg 
q12h given as a 1-hour IV infusion) can provide high PTAs against pathogens 
encountered in real-world practice in the Asia-Pacific region.
Asian CAP patients with moderate renal impairment receiving ceftaroline fosamil 
400 mg q12h had similar or higher PTAs compared with those with normal renal 
function or mild renal impairment receiving ceftaroline fosamil 600 mg q12h. This 
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indicated that the recommended dosage adjustment for ceftaroline fosamil should 
result in adequate PTAs in Asian CAP patients with moderate renal impairment. 
Although patients with severe renal impairment (CrCL 15-30 mL/min) or ESRD 
(CrCL <15 mL/min) were not assessed in this analysis, the finding of similar PK 
between Asian and Western subjects of similar body weight suggests that the 
approved dosage adjustments for Western subjects with severe renal impairment 
(300 mg q12h) and ESRD (200 mg q12h) can also apply to Asian subjects.
The results presented here are to our knowledge the first PTA analyses conducted 
for ceftaroline fosamil specifically for an Asian patient population with CAP. A major 
strength of this analysis is the use of real patient data from a clinical trial of Asian 
patients with CAP in the population PK model. Furthermore, this analysis confirmed 
that high PTAs were achieved at the MIC90 values for contemporary pathogens 
obtained in comprehensive surveillance programs, including those implicated to 
cause CAP in Asia. High PTAs were also achieved at the highest MIC values 
reported for pathogens in the Asia CAP study. It should be noted that in common 
with similar trials, the isolation rate of viable baseline pathogens for culture and 
susceptibility testing was low in this phase 3 study, hence only a limited number of 
isolates were available for inclusion in the analyses. However, the Asia-Pacific 
surveillance data helps to provide assurance that the trial isolates were reflective of 
real-life practice in the region.
Appropriate selection of empirical treatment for CAP should be based on local 
bacterial etiology, which can differ in Asia compared with other regions.31 Some 
epidemiological studies have suggested that S. aureus and Gram-negative bacteria 
such as K. pneumoniae are more commonly associated with CAP in Asia compared 
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with the United States and Europe.31,32 However, consistent with other geographic 
regions, S. pneumoniae was confirmed to be the most commonly identified CAP 
pathogen in Asia in a recent systematic review of data from this region,31 and was 
also the most common pathogen identified in the ceftaroline Asia CAP study.4 
Results from the Asia CAP study suggested that ceftaroline fosamil should be 
regarded as an alternative to ceftriaxone in empirical treatment regimens in this 
patient population.4 Consistent with this finding, the results presented here confirm 
that treatment with ceftaroline fosamil provided high PTAs against these pathogens 
in Asian patients with CAP. Thus, the high PTAs reported in this analysis further 
support for using the ceftaroline fosamil dosing regimens (adjusted for renal function) 
approved in Europe and the United States, which have also shown clinical efficacy in 
the phase 3 Asia CAP study4 for the treatment of Asian patients with CAP. 
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Conclusions
The findings from this population PK model analysis indicate that ceftaroline exhibits 
similar PK in Asian and Western populations. For S. pneumoniae, S. aureus, and 
Enterobacteriaceae, high PTAs (90-100%) were achieved for Asian patients with 
CAP treated with ceftaroline fosamil, which covered the ceftaroline MIC90s recorded 
in recent surveillance studies of these pathogens in the Asia-Pacific region. High 
PTAs were also achieved at the ceftaroline EUCAST and FDA clinical breakpoints 
for these pathogens. These results provide further support for the use of the 
ceftaroline fosamil dosing regimens approved in Europe and the United States to 
treat Asian patients with CAP.
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Figure 1. Population Pharmacokinetic Model Diagnostic Plots for the Final Model, for 
All Subjects in the Western and Asian Datasets Combined 
Panels show observed ceftaroline concentrations versus individual predicted ceftaroline concentrations (IPRED), 
observed ceftaroline concentrations versus population predicted ceftaroline concentrations (PRED), individual 
weighted residual error (IWRES) versus IPRED and conditional weighted residual error (CWRES) versus PRED 
on a semi-logarithmic scale for the final model, IWRES versus TIME and IWRES versus time after last dose 
(TAD) on a linear scale. Individual data points are indicated by gray circles and the points for each individual are 
connected with a line. The red lines represent a smooth, the horizontal black line in the lower panels is the zero 
line, and the diagonal black line in the upper panels is the line of identity.
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Figure 2. Prediction Corrected Visual Predictive Check (pcVPC) for Ceftaroline 
Using the Final Model Based on 1000 Simulated Datasets for All Subjects in the 
Western and Asian Datasets Combined
Data points represent the observed data. Red lines are the 5th, 50th (solid), and 95th percentile based on the 
observed ceftaroline data. The shaded areas are 95% confidence intervals for the 5th, 50th (red), and 95th 
percentile prediction intervals based on the simulated data. 
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Figure 3. PTA for Asian CAP Patients With Normal Renal Function After 
Administration of Ceftaroline Fosamil 600 mg q12h as a 1-Hour Infusion, With PTA 
Plotted as a Function of Ceftaroline MIC Overlaid With Ceftaroline MIC Values for 
448 S. pneumoniae Isolates Obtained During the 2014 AWARE Surveillance 
Program in the Asia-Pacific Region 
CAP, community-acquired pneumonia; MIC, minimum inhibitory concentration; PISP, penicillin-intermediate 
S. pneumoniae (penicillin MIC of 4 mg/L); PRSP, penicillin-resistant S. pneumoniae (penicillin MIC of ≥8 mg/L); 
PSSP, penicillin-susceptible S. pneumoniae (penicillin MIC of ≤2 mg/L); PTA, probability of PK/PD target 
attainment; q12h, every 12 hours. 
The values above the bars are the numbers of isolates tested at each MIC.
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1000 Simulated Datasets for All Subjects in the Western and Asian Datasets Combined 
Data points represent the observed data. Red lines are the 5th, 50th (solid), and 95th percentile based on 
the observed ceftaroline data. The shaded areas are 95% confidence intervals for the 5th, 50th (red), and 
95th percentile prediction intervals based on the simulated data. 
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Figure 3. PTA for Asian CAP Patients With Normal Renal Function After Administration of Ceftaroline Fosamil 
600 mg q12h as a 1-Hour Infusion, With PTA Plotted as a Function of Ceftaroline MIC Overlaid With 
Ceftaroline MIC Values for 448 S. pneumoniae Isolates Obtained During the 2014 AWARE Surveillance 
Program in the Asia-Pacific Region 
CAP, community-acquired pneumonia; MIC, minimum inhibitory concentration; PISP, penicillin-intermediate 
S. pneumoniae (penicillin MIC of 4 mg/L); PRSP, penicillin-resistant S. pneumoniae (penicillin MIC of ≥8 
mg/L); PSSP, penicillin-susceptible S. pneumoniae (penicillin MIC of ≤2 mg/L); PTA, probability of PK/PD 
target attainment; q12h, every 12 hours. 
The values above the bars are the numbers of isolates tested at each MIC. 
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Table 1. Typical Parameter Estimates for the Final Ceftaroline and Ceftaroline 
Fosamil Population PK Model 
Value RSE (%)
Clearance of CPT-F (CLcf), L/h 234 (fixed) NA
Central volume of distribution of CPT-F (Vccf), L 8.25 (fixed) NA
Intercompartmental clearance of CPT-F (Qcf), L/h 17.1 (fixed) NA
Peripheral volume of distribution of CPT-F (Vpcf), L 5.91 (fixed) NA
Absorption rate for CPT-F intra-muscular 
administrationa (Kacf), h-1
0.528 (fixed) NA
Clearance of CPT (CLc), L/h 8.21 2.07
Central volume of distribution of CPT (Vcc), L 10.3 2.75
Intercompartmental clearance of CPT (Qc), L/h 7.75 2.12
Peripheral volume of distribution of CPT (Vpc), L 9.15 1.17
CLc, dialysis, L/h 10.8 1.95
Age on CLc: × (age/36)θ –0.264 9.14
ESRD on CLc: × θ 0.339 13.1
NCrCL on CLc: × (CrCL/80)θ if not dialysis and NCrCL 
<80 mL/min
0.524 5.52
Patient on CLc: × θ 1.26 2.52
Patient on Vcc: × θ 1.59 3.09
IIV CLcf, CV 0.447 (FIX)
IIV Vccf, CV 1.01 (FIX)
IIV Kacf, CV 0.329 (FIX)
IIV CLc,CV 0.211 3.09
IIV Vcc, CV 0.279 4.96
IIV Vcc:CLc, Correlationb 0.571 5.77
IIV Vpc 0.103 10.1
IIV on proportional residual errorc 0.462 3.37
Proportional residual errorcf 0.362 (FIX)
Additive residual errorcf 0.0283 (FIX)
Proportional residual errorc 0.151 2.43
Additive residual errorc 0.0553 2.56
CPT, ceftaroline (when used as subscript designated c); CPT-F, ceftaroline fosamil (when used as subscript 
designated cf); ESRD, end-stage renal disease; NCrCL, normalized creatinine clearance; PK, pharmacokinetic; 
RSE, relative standard error; θ, covariate model parameter; NA, not available due to being fixed for the final 
model.
aCeftaroline fosamil was given by intra-muscular administration in one of the studies included in the model.21
bRSE for the correlation is 0.5 x (SECov/Covariance)
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Table 2. Individual Predicted Ceftaroline Pharmacokinetic Parameters by Ceftaroline 
Fosamil Dosing Regimen for Subjects in the Phase 1 Study in Chinese Healthy 
Volunteers and the Phase 3 Asia CAP Study by dosing regimen
Study/Dosing Regimen
Cmax,ss
(μg/mL)
AUCss
(μgh/mL)
T1/2
(h)
Phase 1, ceftaroline fosamil 600 mg q12h, 1-hour infusion (n = 11)
  Geometric mean (CV) 29.7 (13.6) 66.1 (15.0) 2.13 (7.50)
  Mean (SD) 29.9 (4.25) 66.8 (10.6) 2.14 (0.161)
Phase 1, ceftaroline fosamil 600 mg q8h, 2-hour infusion (n = 14)
  Geometric mean (CV) 22.0 (8.31) 67.3 (8.87) 2.02 (8.19)
  Mean (SD) 22.0 (1.84) 67.6 (6.21) 2.02 (0.160)
Phase 3, ceftaroline fosamil 600 mg q12h, 1-hour infusion (n = 62)
  Geometric mean (CV) 22.2 (19.1) 64.9 (27.1) 2.41 (20.0)
  Mean (SD) 22.5 (4.20) 67.3 (19.2) 2.46 (0.521)
Phase 3, ceftaroline fosamil 400 mg q12h, 1-hour infusion (n = 24)a
  Geometric mean (CV) 17.3 (22.3) 62.2 (20.1) 3.08 (15.1)
  Mean (SD) 17.7 (3.76) 63.4 (12.1) 3.11 (0.566)
AUCss, area under the concentration-time curve at steady state; CAP, community-acquired pneumonia;
Cmax,ss, maximum concentration at steady state; CrCL, creatinine clearance; q8h, every 8 hours; q12h, every 
12 hours; T1/2, terminal half-life.
aPatients with moderate renal impairment (CrCL >30-50 mL/min) in the Asia CAP study received ceftaroline 
fosamil 400 mg q12h as a 1-hour infusion.4
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Table 3. PTA Based on 5000 Simulated Asian CAP Patients With Normal Renal 
Function Achieving PK/PD Targets for S. pneumoniae, S. aureus, and 
Enterobacteriaceae by Ceftaroline MIC After Administration of Ceftaroline Fosamil 
600 mg, as a 1-Hour Intravenous Infusion, q12h
CAP, community-acquired pneumonia; MIC, minimum inhibitory concentration; PD, pharmacodynamic; PK, 
pharmacokinetic; PTA, probability of PK/PD target attainment; q12h, every 12 hours.
PTA (%)
S. pneumoniae S. aureus Enterobacteriaceae
Ceftaroline 
MIC (mg/L)
Stasis 
(35% 
fT>MIC)
1-log10 
kill
(44% 
fT>MIC)
2-log10 
kill
(51% 
fT>MIC)
Stasis
(27% 
fT>MIC)
1-log10 kill
(31% 
fT>MIC)
2-log10 kill
(35% 
fT>MIC)
Stasis
(48.5% 
fT>MIC)
1-log10 kill
(73% 
fT>MIC)
0.125 100 100 100 100 100 100 100 99.9
0.25 100 100 100 100 100 100 100 99.1
0.5 100 100 99.9 100 100 100 100 90.5
1 100 99.6 97.1 100 100 100 98.7 50.5
2 98.6 85.5 61.4 100 99.5 98.6 70.5 6.50
4 53.4 17.2 4.92 86.3 69.7 53.4 7.7 0.06
8 1.36 0.12 0.04 7.60 2.74 1.36 0.04 0.00
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Table 4. PTA Based on 5000 Simulated Asian CAP Patients With Normal Renal 
Function Achieving PK/PD Targets for S. pneumoniae, S. aureus, and 
Enterobacteriaceae at Ceftaroline MIC90s (Based on Isolates Obtained From the 
Asia-Pacific Region in 2012, 2013, and 2014 From the AWARE Ceftaroline 
Surveillance Studies) After Administration of Ceftaroline Fosamil 600 mg as a 1-Hour 
Intravenous Infusion, q12h
CAP, community-acquired pneumonia; MIC, minimum inhibitory concentration; ND, not determined; NR, not 
reported (specific data not collected on ESBL-negative pathogens); PD, pharmacodynamic; PK, pharmacokinetic; 
PTA, probability of PK/PD target attainment; MSSA, methicillin-susceptible S. aureus; PISP, penicillin-
intermediate S. pneumoniae; PRSP, penicillin-resistant S. pneumoniae; PSSP, penicillin-susceptible S. 
pneumoniae; q12h, every 12 hours.
2012 Surveillancea 2013 Surveillanceb 2014 Surveillancec
PTA (%) PTA (%) PTA (%)
Pathogen
MIC90 
(mg/L)
Stasis
1-
log10 
kill
2-
log10 
kill
MIC90
(mg/L)
Stasis
1-log10 
kill
2-log10 
kill
MIC90
(mg/L)
Stasis
1-log10
kill
2-log10
kill
S. pneumoniae
PSSP 0.06 100 100 100 0.12 100 100 100 0.12 100 100 100
PISP 0.25 100 100 100 0.25 100 100 100 0.25 100 100 100
PRSP 0.5 100 100 99.9 0.5 100 100 99.9 1 100 99.6 97.1
S. aureus
All 2 100 99.5 98.6 2 100 99.5 98.6 2 100 99.5 98.6
MSSA 0.25 100 100 100 0.25 100 100 100 0.25 100 100 100
Enterobacteriaceae
All E. coli >128 0 0 ND >128 0 0 ND >128 0 0 ND
ESBL-negative 
E. colid
NR ND ND ND 0.5 100 90.5 ND 0.5 100 90.5 ND
All K. 
pneumoniae
>128 0 0 ND >128 0 0 ND >128 0 0 ND
ESBL-negative K. 
pneumoniaed NR ND ND ND 0.25 100 99.1 ND 0.25 100 99.1 ND
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aBased on 406 S. pneumoniae (310 PSSP, 81 PISP, and 15 PRSP), 532 K. pneumoniae, and 779 E. coli isolates 
collected in the 2012 AWARE surveillance study. bBased on 530 S. pneumoniae (406 PSSP, 96 PISP, and 28 
PRSP), 2595 S. aureus (1021 MSSA), 718 K. pneumoniae (472 ESBL-negative), and 1017 E. coli (639 ESBL-
negative) isolates collected in the 2013 AWARE surveillance study.
cBased on 448 S. pneumoniae (394 PSSP, 33 PISP, and 21 PRSP), 1640 S. aureus (622 MSSA), 639 K. 
pneumoniae (412 ESBL-negative), and 700 E. coli (439 ESBL-negative) isolates collected in the 2014 AWARE 
surveillance study.
dA ceftazidime or aztreonam MIC >1 mg/L was used as a phenotypic marker to define ESBL-positive isolates. 
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Table 5. PTA Based on 5000 Simulated Asian CAP Patients With Normal Renal 
Function Achieving Species-Specific and Non–species-specific PK/PD Targets at 
EUCAST and FDA/CLSI Breakpoints After Administration of Ceftaroline Fosamil 600 
mg, as a 1-hour Infusion q12h
CAP, community-acquired pneumonia; MIC, minimum inhibitory concentration; ND, not determined; PD, 
pharmacodynamic; PK, pharmacokinetic; PTA, probability of PK/PD target attainment; q12h, every 12 hours.
aFDA/CLSI breakpoint.
bEUCAST breakpoint.
PTA (%)
Pathogen
Susceptible MIC 
Breakpoint 
(mg/L)
Stasis 1-log10 kill 2-log10 kill
S. pneumoniae ≤0.5a 100 100 99.9
≤0.25b 100 100 100
S. aureus ≤1a,b 100 100 100
Enterobacteriaceae ≤0.5a,b 100 90.5 ND
H. influenzae ≤0.5a
≤0.03b
>90% at a PK/PD target of ≥70% fT>MIC
100% at a PK/PD target of 100% fT>MIC
Non–species-specific ≤0.5b >90% at a PK/PD target of ≥70% fT>MIC
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Supplementary Material
Population Pharmacokinetic Modeling and Probability of 
Target Attainment Analyses in Asian Patients With 
Community-Acquired Pneumonia Treated With Ceftaroline 
Fosamil
Jianguo Li, Shampa Das, Diansong Zhou, and Nidal Al-Huniti
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Bioanalytical Methods
Ceftaroline fosamil, ceftaroline and ceftaroline M-1 concentrations in plasma samples 
were determined using validated liquid chromatography coupled with tandem mass 
spectrometry (LC–MS/MS; Covance Bioanalytical Services LLC, Indianapolis, IN, USA) 
methods in each study, with the exception of study P903-17, which used a validated 
high-performance liquid chromatography (HPLC)-ultraviolet detection method. Plasma 
samples (50 μL) were combined with equal amounts of the corresponding stable isotope 
labelled internal standards (ceftaroline fosamil-d3, ceftaroline-d3, or ceftaroline M-1-d3), 
and chilled methanol was subsequently added to induce protein-precipitation. The 
resulting supernatants were evaporated to dryness, reconstituted with 20 mM 
ammonium formate and chromatographic separation was achieved using a Waters 
Atlantis dC18 column (150 by 2.1 mm, 5 μm particle size) with a gradient mobile phase 
consisting of ammonium formate, isopropyl alcohol, methanol, water, and a flow rate of 
0.6 ml/min. Analytes were detected by electrospray ionisation (ESI) mass spectrometry 
with multiple-reaction monitoring (MRM) of positive ions. The MRM in positive ion mode 
used precursor→product ions of m/z 685.0→208.0, m/z 605.0→209.0, m/z 
623.1→209.0, m/z 688.0→211.0, m/z 608.1→212.0, and m/z 626.1→212.0 to monitor 
ceftaroline fosamil, ceftaroline, ceftaroline M-1, and their internal standards, ceftaroline 
fosamil-d3, ceftaroline-d3, or ceftaroline M-1-d3. Quantification was directly determined 
from the ratio of the analyte peak area to their respective stable isotope labelled internal 
standard compound. The lower limit of quantification for all analytes (LLOQ) was 0.05 
μg/mL in each study, with the exception of studies P903-1, P903-2 and P903-3, which 
used a LLOQ of 0.01 μg/mL. At the LLOQ, intra-day accuracy (percent bias) and intra-
day precision (% coefficient of variation) were within the ranges of ±6.2% to ±8.4% and 
≤6.1% to ≤6.8%, respectively. Inter-day accuracy and inter-day precision at the LLOQ 
ranged from ±4.3% to ±8.7% and ≤5.9% to ≤6.5%, respectively. 
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Table S1 Summary of Studies Included in the Analysis Dataset for the Final Model
Name/Study protocol 
number 
(clinicaltrials.gov 
registration, if 
available)
Description LLOQ in plasma
Phase 1
CXL-PK-011 A phase 1 study of single and multiple 
intravenous doses of ceftaroline fosamil 
and avibactam in healthy subjects
0.05 μg/mL
P903-012 A phase 1, randomized, double-blind, 
placebo controlled, 2 part, single and 
multiple ascending dose study of 
ceftaroline fosamil in healthy adults
0.01 μg/mL.
P903-022 A phase 1 open-label study of single 
intravenous doses of ceftaroline fosamil 
in subjects with normal renal function, 
mild renal impairment, or moderate 
renal impairment
0.01 μg/mL 
P903-042 An open-label pharmacokinetic, safety, 
and tolerability study of single 
intravenous doses of ceftaroline fosamil 
in subjects with normal renal function or 
severe renal impairment
0.05 μg/mL 
P903-112 An open-label pharmacokin tic, safety, 
and tolerability study of single 
intravenous doses of ceftaroline in 
healthy elderly and healthy young adult 
subjects
0.05 μg/mL 
P903-132 A single-dose, open-label study to 
assess the metabolism, elimination and 
safety of ceftaroline prodrug after 
intravenous administration of [14C] 
ceftaroline fosamil in healthy subjects
0.05 μg/mL 
P903-143 A phase 1, multiple-dose, open-label 
study to assess the effect of ceftaroline 
on the intestinal microflora of healthy 
human subjects
0.05 μg/mL
P903-15 
(NCT00633126)4
Pharmacokinetics of a single dose of 
ceftaroline in subjects 12 to 17 years of 
age receiving empiric parenteral 
antibiotic therapy for suspected 
infections
0.05 μg/mL
P903-175 A phase 1, two-part, single- and 
multiple-dose study to determine the 
safety, tolerability and 
0.05 μg/mL 
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pharmacokinetics of ceftaroline fosamil 
administered by intramuscular injection 
in healthy subjects
P903-182 An open-label pharmacokinetic, safety, 
and tolerability study of single 
intravenous doses of ceftaroline fosamil 
in subjects with end-stage renal 
disease (ESRD) on intermittent 
haemodialysis and subjects with normal 
renal function
0.05 μg/mL
P903-20 (data on file) A phase 1, randomized, double-blind, 
placebo-controlled study to determine 
the safety and pharmacokinetics of 
single doses (Part A) and multiple-dose 
regimens (Part B) of ceftaroline in 
healthy subjects
0.05 μg/mL 
D3720C00005
(NCT01458743)6
A phase 1 open-label study to 
assess the safety and 
pharmacokinetics of ceftaroline in 
healthy Chinese volunteers 
following single and multiple 
administration of 600 mg ceftaroline 
fosamil as 60-minute intravenous 
infusion every 12 hours and as 120-
minute intravenous infusion every 8 
hours
0.05 μg/mL 
Phase 2
P903-037 A phase 2, multicenter, randomized, 
observer-blinded study to evaluate the 
safety and efficacy of ceftaroline 
fosamil versus standard therapy in 
adult subjects with complicated skin 
and skin structure infections
0.01 μg/mL 
Phase 3
CANVAS 1/P903-06 
(NCT00424190)8
A phase 3, multicenter, randomized, 
double-blind, comparative study to 
evaluate the safety and efficacy of 
ceftaroline versus vancomycin plus 
aztreonam in adult subjects with 
complicated skin and skin structure 
infection
0.05 μg/mL 
CANVAS 2/P903-07 
(NCT00423657)9
A phase 3, multicenter, randomized, 
double-blind, comparative study to 
evaluate the safety and efficacy of 
ceftaroline versus vancomycin plus 
aztreonam in adult subjects with 
complicated skin and skin structure 
infection
0.05 μg/mL 
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FOCUS 1/P903-08
(NCT00621504)10
A phase 3, multicenter, randomized, 
double-blind, comparative study to 
evaluate the safety and efficacy of 
ceftaroline versus ceftriaxone, with 
adjunctive clarithromycin, in the 
treatment of adult subjects with 
community-acquired pneumonia
0.05 μg/mL 
FOCUS 2/P903-09
(NCT00509106)11
A phase 3, multicenter, randomized, 
double-blind, comparative study to 
evaluate the safety and efficacy of 
ceftaroline versus ceftriaxone in the 
treatment of adult subjects with 
community-acquired pneumonia
0.05 μg/mL
Asia 
CAP/D3720C00002 
(NCT01371838)12
A phase 3, multicentre, randomized, 
double-blind, comparative study to 
evaluate the efficacy and safety of 
intravenous ceftaroline fosamil 
versus intravenous ceftriaxone in 
the treatment of adult hospitalized 
patients with community-acquired 
bacterial pneumonia in Asia
0.05 μg/mL
Studies in Asian patients indicated with bold font. Validated LC-MS/MS methods were used to determine plasma concentrations of 
ceftaroline and ceftaroline fosamil in each study apart from study P903-17, which used a validated HPLC method.13
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Table S2. Summary of Baseline Covariates Included in the Analysis Dataset for the 
Final Population PK Model 
Western Dataset
N = 421
New Asian Studies
N = 112
All Data
N = 533
Age (years) 42 (12, 88) 65 (19, 93) 47 (12, 93)
Body weight (kg) 74 (40, 134) 62 (45, 86) 72 (40, 134)
BMI (kg/m2) 24.6 (17.5, 38.2) 22.6 (15.6, 30.4) 24.2 (15.6, 38.2)
BSA (m2) 1.90 (1.28, 2.58) 1.66 (1.37, 2.00) 1.84 (1.28, 2.58)
BSA normalized CrCL 
(mL/min)/(1.73 m2)
93.0 (8.2, 268.6) 81.2 (35.9, 156.1) 92.0 (8.2, 268.6)
Height (cm) 174 (147, 195) 165 (141, 178) 172 (141, 195)
Dialysis status 
No dialysis  415 (99%)  112 (100%)  527 (99%) 
ESRD 6 (1%) 0 (0%) 6 (1%) 
Dialysis 0 (0%) 0 (0%) 0 (0%) 
Renal function 
Normal 
(CrCL >80 mL/min)
266 (63%) 54 (48%) 320 (60%) 
Mild renal impairment
(CrCL >50-80 mL/min)
107 (25%) 39 (35%) 146 (27%) 
Moderate renal 
impairment (CrCL >30-
50 mL/min)
33 (8%) 19 (17%) 52 (10%) 
Severe renal 
impairment 
(CrCL 15-30 mL/min) 
9 (2%) 0 (0%) 9 (2%) 
ESRD or dialysis
(CrCL <15 mL/min)
6 (1%) 0 (0%) 6 (1%) 
Patient status
Healthy volunteer 195 (46%) 26 (23%) 221 (41%) 
Patient 226 (54%) 86 (77%) 312 (59%) 
Race
Caucasian 306 (73%) 0 (0%)  306 (57%) 
Black 54 (13%)  0 (0%) 54 (10%) 
Asiana 11 (3%) 112 (100%) 123 (23%) 
Other 50 (12%) 0 (0%) 50 (9%) 
Sex
Male 271 (64%) 77 (69%) 348 (65%) 
Female 150 (36%) 35 (31%) 185 (35%) 
BMI, body mass index; BSA, body surface area; CrCL, creatinine clearance; ESRD, end-stage renal disease.
Data presented as median (min, max) or n (%).
aAsian includes Indians.
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Table S3. PTA Based on 5000 Simulated Asian Patients With CAP Achieving Non–
Species-Specific %fT>MIC PK/PD Targets at Steady State by Ceftaroline MIC Value 
After Administration of Ceftaroline Fosamil 600 mg as a 1-Hour Intravenous Infusion, 
q12h 
CAP, community-acquired pneumonia; MIC, minimum inhibitory concentration; PD, pharmacodynamic; PK, 
pharmacokinetic; PTA, probability of PK/PD target attainment; q12h, every 12 hours.
aMICs <0.125 mg/L have 100% PTA for all PK/PD targets.
PTA, %
Ceftaroline 
MIC 
(mg/L)
fT>MIC = 
20%
fT>MIC = 
30%
fT>MIC = 
40%
fT>MIC = 
50%
fT>MIC = 
60%
fT>MIC = 
70%
fT>MIC = 
80%
0.125a 100 100 100 100 100 100 99.8
0.25 100 100 100 100 100 99.6 96.9
0.5 100 100 100 100 99.2 94.3 78.3
1 100 100 99.9 98.2 86.7 60.2 31.1
2 100 99.7 94.1 67.4 31.1 9.76 2.62
4 99.4 76.9 30.7 6.72 1.06 0.18 0.02
8 37.7 4.20 0.26 0.04 0.00 0.00 0.00
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Table S4. PTA Based on 5000 Simulated Asian CAP Patients With Mild Renal 
Impairment Achieving PK/PD Targets for S. pneumoniae, S. aureus, and 
Enterobacteriaceae by Ceftaroline MIC After Administration of 600 mg Ceftaroline 
Fosamil as a 1-Hour Intravenous Infusion, q12h 
PTA, %
S. pneumoniae S. aureus EnterobacteriaceaeCeftaroline 
MIC (mg/L)
Stasis
(35% 
fT>MIC)
1-log
10
 kill
(44% 
fT>MIC)
2-log
10
 kill
(51% 
fT>MIC)
Stasis
(27% 
fT>MIC)
1-log
10
 kill
(31% 
fT>MIC)
2-log
10
 kill
(35% 
fT>MIC)
Stasis
(48.5% 
fT>MIC)
1-log
10
 kill
(73% 
fT>MIC)
0.125 100 100 100 100 100 100 100 99.9
0.25 100 100 100 100 100 100 100 99.9
0.5 100 100 100 100 100 100 100 97.7
1 100 100 99.6 100 100 100 99.8 79.0
2 99.8 96.4 86.0 100 100 99.8 90.7 27.2
4 80.3 45.8 22.6 96.3 89.2 80.3 29.1 1.26
8 7.10 1.34 0.42 25.5 13.3 7.10 0.62 0.00
CAP, community-acquired pneumonia; MIC, minimum inhibitory concentration; PD, pharmacodynamic; PK, 
pharmacokinetic; PTA, probability of PK/PD target attainment; q12h, every 12 hours.
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Table S5. PTA for 5000 Simulated Asian CAP Patients With Moderate Renal 
Impairment Achieving the PK/PD Targets for S. pneumoniae, S. aureus, and 
Enterobacteriaceae by Ceftaroline MIC After Administration of 400 mg Ceftaroline 
Fosamil as 1-Hour Intravenous Infusion, q12h 
PTA, %
S. pneumoniae S. aureus Enterobacteriaceae
Ceftaroline 
MIC (mg/L)
Stasis
(35% 
fT>MIC)
1-log
10
 kill
(44% 
fT>MIC)
2-log
10
 kill
(51% 
fT>MIC)
Stasis
(27% 
fT>MIC)
1-log
10
 kill
(31% 
fT>MIC)
2-log
10
 kill
(35% 
fT>MIC)
Stasis
(48.5% 
fT>MIC)
1-log
10
 kill
(73% 
fT>MIC)
0.125 100 100 100 100 100 100 100 100
0.25 100 100 100 100 100 100 100 100
0.5 100 100 100 100 100 100 100 100
1 100 100 99.9 100 100 100 100 91.6
2 99.9 97.7 91.5 100 100 99.9 94.1 43.0
4 76.2 47.1 26.7 93.7 85.7 76.2 32.8 2.28
8 4.20 1.12 0.22 14.6 7.68 4.20 0.42 0.00
CAP, community-acquired pneumonia; MIC, minimum inhibitory concentration; PD, pharmacodynamic; PK, 
pharmacokinetic; PTA, probability of PK/PD target attainment; q12h, every 12 hours.
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Figure S1. Prediction Corrected Visual Predictive Check for Ceftaroline Using the Final 
Model Based on 1000 Simulated Datasets for Patients From the Phase 3 Asia CAP 
Study. 
CAP, community-acquired pneumonia.
The red lines are the 5th, 50th (solid), and 95th percentile based on the observed data. The shaded areas are 95% 
confidence intervals for the 5th, 50th (red), and 95th percentile prediction intervals based on the simulated data.
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Figure S2. Population Pharmacokinetic Model Diagnostic Plots for Ceftaroline After 
Reintroducing Ceftaroline Fosamil Concentrations Into the Final Model
Panels show observed ceftaroline concentrations versus individual predicted ceftaroline concentrations (IPRED), 
observed ceftaroline concentrations versus population predicted ceftaroline concentrations (PRED), individual 
weighted residual error (IWRES) versus IPRED and conditional weighted residual error (CWRES) versus PRED on a 
semi-logarithmic scale for the final model, IWRES versus TIME and IWRES versus time after last dose (TAD) on a 
linear scale. Individual data points are indicated by gray circles and the points for each individual are connected with 
a line. The red lines represent a smooth, the horizontal black line in the lower panels is the zero line, and the diagonal 
black line in the upper panels is the line of identity.
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Figure S3. Prediction Corrected Visual Predictive Check for Ceftaroline After 
Reintroducing Ceftaroline Fosamil Concentrations Into the Final Model Based on 1000 
Simulated Datasets for All Subjects in the Western and Asian Datasets Combined
Data points represent the observed data. Red lines are the 5th, 50th (solid), and 95th percentile based on the 
observed ceftaroline data. The shaded areas are 95% confidence intervals for the 5th, 50th (red), and 95th percentile 
prediction intervals based on the simulated data
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